May 16, 2023

Dermavant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old

READ MORE

March 15, 2023

Dermavant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old

READ MORE

March 10, 2023

Dermavant to Present Data from Multiple Studies of VTAMA® (tapinarof) cream, 1% at the 2023 American Academy of Dermatology Annual Meeting

READ MORE

February 13, 2023

Dermavant Completes Enrollment of Two Phase 3 Clinical Trials of VTAMA® (tapinarof) cream, 1% for the treatment of Atopic Dermatitis in Adults and Children as Young as 2 years old

READ MORE

January 12, 2023

Dermavant to Present Data from Multiple Studies of VTAMA® (tapinarof) cream, 1% at the 2023 Winter Clinical Dermatology Conference  

READ MORE

November 22, 2022

Dermavant Launches First Commercial for VTAMA® (tapinarof) cream, 1% as Part of a National, Multimedia Campaign for Adults with Plaque Psoriasis

READ MORE